The Food and Drug Administration has approved a topical wipe that can help reduce excessive sweating of the armpits, the company announced on Friday.
Qbrexza is a cloth that can be applied to the skin daily to reduce sweat through sweat gland activation, according to a message from manufacturer Dermira. The product provides a subtle solution for millions of people suffering from primary focal axillary hyperhidrosis or excessive underarm sweating that is currently often treated with Botox and other more invasive options.
Two clinical studies have shown that Qbrexza decreases sweat production and severity of patients, according to Dermira. Possible side effects include dryness of the skin, mouth, eyes, nose and throat; Sore throat; A headache; blurred vision and dilated pupils; and urinate constipation and problems.
The product is approved for patients nine and older, and is expected to open pharmacies in October, according to the announcement. Dermira has not published pricing information.